A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance - Takeaways - MDSpire
Clinical Guidelines

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

  • By

  • Kimberly Noonan, DNP, ANP-BC, AOCN, FAAN

  • Kevin Brigle, PhD, ANP

  • Charise Gleason, MSN, NP-C, AOCNP

  • Carrie Bellerive, BS, RN, BMTCN

  • Mary Steinbach, DNP, APRN

  • Deborah Doss, RN, OCN

  • March 4, 2026

  • 17 min

Share

  • 1

    MGUS is asymptomatic and can progress to multiple myeloma.

  • 2

    Risk stratification is crucial for determining management.

  • 3

    Ms. Jones presents with intermediate-risk MGUS.

  • 4

    Long-term monitoring is essential for MGUS.

  • 5

    Genetic markers influence progression risk.

  • 6

    Multidisciplinary approaches improve patient outcomes.

  • 7

    New models like PANGEA provide insights into cancer progression.

  • 8

    Education of healthcare providers on MGUS characteristics is needed.

Original Source(s)

Related Content